title: High-dose treatment with vitamin A analogues and risk of fractures.
abstract: OBJECTIVE
  To study fracture risk associated with use of systemic vitamin A analogue (isotretinoin and acitretin) treatment.
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  Nationwide registry.
  
  
  METHODS
  A total of 124 655 patients with fractures (cases) and 373 962 age- and sex-matched controls. Main Outcome Measure Incidence of fractures in patients with and without exposure to systemic vitamin A analogues. Confounder control was performed for social variables, contacts with hospitals and general practitioners, alcoholism, and a number of other variables known to potentially affect fracture risk, including use of systemic, intramuscular, and topical corticosteroids and antiepileptic drugs and comorbid conditions.
  
  
  RESULTS
  No trend in risk of any fracture or of hip, forearm, or spine fractures was present with increasing doses or durations of treatment with vitamin A analogues. Subdividing vitamin A analogues into isotretinoin and acitretin did not change the results.
  
  
  CONCLUSIONS
  Risk of fracture is not associated with vitamin A analogue treatment.
authors.affiliation: The Osteoporosis Clinic, Aarhus Amtssygehus, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark. p-vest@post4.tele.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Vestergaard
authors.forename: Lars
authors.initials: L
authors.lastname: Rejnmark
authors.forename: Leif
authors.initials: L
authors.lastname: Mosekilde
mesh_terms: D017255:Acitretin / Q000008:administration & dosage / Q000009:adverse effects*; D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003718:Denmark; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced*; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000009:adverse effects*; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012042:Registries; D018570:Risk Assessment; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D007641:Keratolytic Agents; D015474:Isotretinoin; D017255:Acitretin